Articles

This research is a collaboration involving a university team, a partnering corporation, and a hemodialysis clinic, which is a cross-disciplinary research initiative in the field of Artificial Intelligence of Things (AIoT) within the medical informatics domain. The research has two objectives: (1) The development of an <i>Internet of Things (IoT)</i><i>-based</i><i> Information System</i> customized for the hemodialysis machines at the clinic, including transmission bridges, clinical personnel dedicated web/app, and a backend server. The system has been deployed at the clinic and is now officially operational; (2) The research also utilized de-identified, anonymous data (collected by the officially operational system) to train, evaluate, and compare <i>Deep Learning-based Intradialytic Blood Pressure</i><i> (BP)</i><i>/Pulse </i><i>Rate (PR) </i><i>Predictive Models</i>, with subsequent suggestions provided. Both objectives were executed under the supervision of the Institutional Review Board (IRB) at Mackay Memorial Hospital in Taiwan. The system completed for objective one has introduced three significant services to the clinic, including automated hemodialysis data collection, digitized data storage, and an information-rich human-machine interface as well as graphical data displays, which replaces traditional paper-based clinical administrative operations, thereby enhancing healthcare efficiency. The graphical data presented through web and app interfaces aids in real-time, intuitive comprehension of the patients’ conditions during hemodialysis. Moreover, the data stored in the backend database is available for physicians to conduct relevant analyses, unearth insights into medical practices, and provide precise medical care for individual patients. The training and evaluation of the predictive models for objective two, along with related comparisons, analyses, and recommendations, suggest that in situations with limited computational resources and data, an Artificial Neural Network (ANN) model with six hidden layers, SELU activation function, and a focus on artery-related features can be employed for hourly intradialytic BP/PR prediction tasks. It is believed that this contributes to the collaborating clinic and relevant research communities.

The management of supply chains is increasingly complex. This study provides a comparative analysis of the cost-benefit analysis for managing various risks. It identifies the financial implications of leveraging artificial intelligence in supply chains to better address risk. Empirical results show a business case for managing some sources of risk more proactively facilitated through predictive modeling techniques offered by AI. Across investigation streams, the use of AI results in an average total cost saving ranging from 41,254 to 4,099,617. Findings from our research can be used to inform managers and theorists about the implications of integrating AI technologies to manage risks in the supply chain. Our work also highlights areas for future research. Given the growing interest in studying sub-second forecasting, our research could be a point of departure for future investigations aimed at considering the impact of forecasting horizons such as an intra-day basis. We formulate a conceptual framework that considers how and to what extent performance evaluation metrics vary according to differences in the fidelity of predictive models and factor importance for identifying risks. We also utilize a mixed-method approach to demonstrate the applicability of our ideas in practice. Our results illustrate the financial implications of integrating AI predictive tools with business processes. Results suggest that real-world companies can circumvent inefficiencies associated with trying to manage many classes of risk via the use of AI-enhanced predictive analytics. As managers need to justify investment to top management, our work supports decision-making by providing a means of conducting a trade-off analysis at the tactical level.

The effects on the elderly are disproportionately Alzheimer’s disease (AD) is one of the most prevalent and chronic types of dementia. Alzheimer's disease (AD), a fatal illness that can harm brain structures and cells long before symptoms appear, is currently incurable and incurable. Using brain MRI pictures from a publicly accessible Kaggle dataset, this study suggests a prediction model based on Convolutional Neural Networks (CNNs) to help with the early detection of Alzheimer's disease. Four levels of dementia have been applied to the 6,400 photos in the collection: not demented, slightly demented, moderately demented, and considerably mildly demented. Pixel normalization, class balancing utilizing data augmentation techniques, and picture scaling to 128×128 pixels were all part of a thorough workflow for data preparation. To improve the gathering of spatial dependence in volumetric MRI data, a 3D convolutional neural network (CNN) architecture was used. We used important performance measures including F1-score, recall, accuracy, precision, and log loss to gauge the model's effectiveness. A review of the available data indicates that the total F1-score, accuracy, recall, and precision were 99.0%, 99.0%, and 99.38%, respectively. The findings demonstrate the model's potential for practical use in early AD diagnosis and establish its robustness with the help of confusion matrix analysis and performance curves.

Biopharmaceuticals, or biologics, are a burgeoning sector in the pharmaceutical industry, predicted to reach $239.4 billion by 2025. This unparalleled growth is often attributed to the enhanced specificity offered by large molecules over small molecules. The large size of the constituent proteins necessitates the continuous implementation of big data predictive analytics to elucidate the most effective candidates in the lead optimization process. These same methodologies can be applied, and with the advent of machine learning and automated predictive analytics, this is becoming an increasingly facile task, to the augmentation and optimization of the downstream production processes that comprise the majority of the development cost of any biologic. In this work, big data from cell line generation, product and process design, and large-scale lead validation studies have been used to compare the applicability of simple statistical models against these black-box approaches for the rapid acceleration of enzymes to the pilot plant stage. This research can be expanded upon to exploit the big datasets generated as part of the progression of biologics through the development pipeline to further optimize production outcomes. Over the coming months, data from the project will be used to probe which approaches are amenable to which processes and, as a result, more amenable to various economic simulations. The computed optimization objective for the HIT must include the cost of acquiring, storing, and analyzing data to construct these predictive models, alongside the expected commercial reward of choosing an optimally ranked candidate. In this vein, perspective must be taken in the probable future price, capability outputs, and ownership issues of increasingly sophisticated data analysis software as superstructures become more frequent. It is frequently stated that decisions made to reduce production costs are data-driven, but that is not because more economically or energetically costly experiments or production methods are employed; to truly evaluate production steps, dynamic energy, and economic models need to become more commonplace. Conversion of process quality approaches from large questionnaires, risk analysis, and expert opinion-driven methods to statistical and thus more reliable approaches is an area of future research in analytics used herein.